Skip to main content

Table 1 Comparisons of multiple factors between RP-ILD and non-RP-ILD groups

From: The lungs were on fire: a pilot study of 18F-FDG PET/CT in idiopathic-inflammatory-myopathy-related interstitial lung disease

Factors RP-ILD (21) Non-RP-ILD (40) P value P-adjusted
Age(y) 54.86 ± 11.72 57.70 ± 11.06 0.354 0.824
Sex (male/female) 8/13 17/23 0.740 1.000
Course of disease(m) 2.00 (1.00, 2.75) 2.25 (1.00, 5.00) 0.253 0.748
Duration of diagnosis delay(m) 1.50 (0.50, 2.00) 1.00 (1.00, 3.00) 0.274 0.756
Clinical manifestations or complications  
 Pulmonary bacterial infection 7 (33.3%) 4 (10.0%) 0.036 0.347
 Pulmonary fungal infection 5 (23.8%) 4 (10.0%) 0.253 0.748
 Tuberculosis infection 0 (0.0%) 0 (0.0%) NA NA
 EBV infection 6 (28.6%) 5 (12.5%) 0.164 0.605
 CMV infection 2 (9.5%) 0 (0.0%) 0.115 0.559
 Carcinoma 1 (4.8%) 6 (15.0%) 0.405 0.824
 Gastrointestinal haemorrhage 4 (19.0%) 1 (2.5%) 0.044 0.347
 UIP pattern 3 (14.3%) 4 (10.0%) 0.683 0.962
 Pneumomediastinum 1 (4.8%) 1 (2.5%) 1.000 1.000
Laboratory finding
 Ferritin (ng/ml) 612.50 (302.05, 2110.25) 664.05 (314.40, 2061.23) 0.495 0.863
 ESR (mm/h) 16.00 (6.50, 32.00) 17.50 (9.50, 42.00) 0.466 0.857
 CRP (mg/L) 5.40 (3.10, 19.80) 6.35 (3.00, 36.73) 0.660 0.962
 ALT(U/L) 37.00 (22.50, 99.50) 91.50 (33.75, 212.50) 0.051 0.347
 AST(U/L) 45.00 (33.00, 97.00) 54.50 (34.00, 235.50) 0.224 0.725
 LDH(U/L) 329.00 (275.50, 478.50) 323.00 (247.75, 461.50) 0.897 1.000
 CK(U/L) 84.00 (50.50, 255.00) 86.00 (44.25, 415.25) 0.838 1.000
Disease activity  
 MYOACT score 13.00 (9.00, 15.50) 9.00 (7.00, 10.75) 0.006 0.102
Lung function testing  
 FVC% (%) 65.33 ± 20.08 71.86 ± 15.61 0.165 0.605
 FEV1% (%) 64.85 ± 19.40 74.42 ± 18.25 0.062 0.383
 FEV1/FVC 0.81 (0.75, 0.85) 0.81 (0.77,0.85) 0.849 1.000
 TLC(L) 3.43 ± 1.01 3.98 ± 1.02 0.049 0.347
 DLCO% (%) 50.29 ± 15.58 66.92 ± 16.67 < 0.001 0.014
18F-FDG PET/CT scan findings
 Time gap after RS onset*(d) 20.00 (12.50, 25.00) 16.50 (13.00, 24.75) 0.767 1.000
 Bilateral lung SUVmean 0.60 ± 0.15 0.45 ± 0.14 < 0.001 0.014
 Abnormal mediastinal lymph node 14 (66.7%) 10 (25.0%) 0.002 0.045
 Abnormal hilar lymph node 11 (52.4%) 9 (22.5%) 0.018 0.204
 Liver SUVmean 1.83 ± 0.34 1.73 ± 0.47 0.412 0.824
 Spleen SUVmean 2.02 ± 0.50 1.82 ± 0.46 0.126 0.571
 Bone marrow SUVmean 1.72 ± 0.50 1.62 ± 0.44 0.402 0.824
 Cardiac SUVmean 1.38 (1.00, 2.03) 1.60 (1.12, 2.39) 0.379 0.824
 Oesophagus SUVmean 1.51 (1.19, 1.83) 1.34 (1.07, 1.74) 0.213 0.724
 Stomach SUVmean 0.69 (0.49, 1.00) 0.71 (0.57, 0.83) 0.927 1.000
 Small intestine SUVmean 1.05 ± 0.33 1.03 ± 0.32 0.878 1.000
 Colon and rectum SUVmean 1.07 (0.80, 1.32) 1.02 (0.83, 1.20) 0.693 0.962
 Bilateral cerebellum SUVmean 5.17 ± 1.26 5.24 ± 1.61 0.863 1.000
 Bilateral trapezius SUVmean 0.82 (0.70, 0.96) 0.79 (0.68, 1.00) 0.585 0.944
 Bilateral deltoid SUVmean 0.71 (0.58, 1.27) 0.78 (0.61, 1.09) 0.590 0.944
 Bilateral biceps SUVmean 0.75 (0.67, 1.01) 0.77 (0.60, 1.10) 0.879 1.000
 Bilateral iliopsoas SUVmean 1.10 ± 0.36 1.12 ± 0.36 0.850 1.000
 Bilateral gluteus maximus SUVmean 0.85 ± 0.27 0.79 ± 0.32 0.462 0.857
 Bilateral gluteus medius SUVmean 0.92 ± 0.29 0.98 ± 0.29 0.473 0.857
 Bilateral quadriceps SUVmean 0.78 (0.62, 0.96) 0.82 (0.69, 1.05) 0.370 0.824
Myositis-specific antibodies and myositis-associated antibodies  
 Anti-MDA5 13 (61.9%) 12 (30.0%) 0.016 0.204
 Anti-PL-7 4 (19.0%) 2 (5.0%) 0.169 0.605
 Anti-PL-12 1 (4.8%) 1 (2.5%) 1.000 1.000
 Anti-EJ 0 (0.0%) 1 (2.5%) 1.000 1.000
 Anti-OJ 0 (0.0%) 1 (2.5%) 1.000 1.000
 Anti-Jo-1 2 (9.5%) 3 (7.5%) 1.000 1.000
 Anti-TIF1γ 1 (4.8%) 3 (7.5%) 1.000 1.000
 Anti-Mi-2α 0 (0.0%) 2 (5.0%) 0.541 0.920
 Anti-Mi-2β 0 (0.0%) 4 (10.0%) 0.289 0.756
 Anti-SAE1 0 (0.0%) 5 (12.5%) 0.154 0.605
 Anti-NXP2 1 (4.8%) 6 (15.0%) 0.405 0.824
 Anti-SRP 1 (4.8%) 2 (5.0%) 1.000 1.000
 Anti-Ku 1 (4.8%) 1 (2.5%) 1.000 1.000
 Anti-PM-Scl75 1 (4.8%) 2 (5.0%) 1.000 1.000
 Anti-PM-Scl100 0 (0.0%) 0 (0.0%) NA NA
 Anti-Ro-52 14 (66.7%) 17 (42.5%) 0.073 0.414
Therapies  
 Steroid monotherapy 6 (28.6%) 14 (35.0%) 0.611 0.944
 Steroid + DMARDs 7 (33.3%) 19 (47.5%) 0.288 0.756
 Steroid+IVIG 2 (9.5%) 2 (5.0%) 0.602 0.944
 Steroid+DMARDs+IVIG 3 (14.3%) 4 (10.0%) 0.683 0.962
 Steroid + JAK inhibitor 3 (14.3%) 1 (2.5%) 0.113 0.559
IIM subtypes  
 DM 13 (61.9%) 27 (67.5%) 0.662 0.962
 PM 2 (9.5%) 7 (17.5%) 0.479 0.857
 ADM 6 (28.6%) 6 (15.0%) 0.309 0.778
  1. RP-ILD, rapidly progressive interstitial lung disease; P-adjusted, adjusted P value after false discovery rate correction; y, years; m, months; NA, not available; EBV, Epstein-Barr virus; CMV, cytomegalovirus; UIP pattern, usual interstitial pneumonia pattern; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ALT, alanine transaminase; AST, aspartate transaminase; LDH, lactate dehydrogenase; CK, creatine kinase; MYOACT, Myositis Disease Activity Assessment Visual Analogue Scales; FVC%, percent-predicted forced vital capacity; FEV1%, percent-predicted forced expiratory volume in 1 s; FEV1/FVC, ratio of FEV1 over FVC; TLC, total lung capacity; DLCO%, percent-predicted diffusing capacity of the lung for carbon monoxide; RS, respiratory symptoms; d, days; FDG, fluorodeoxyglucose; SUVmean, mean standard uptake value; DMARDs, disease-modifying anti-rheumatic drugs; IVIG, intravenous immunoglobulin; JAK, Janus kinase; IIM, idiopathic inflammatory myopathy; DM, dermatomyositis; PM, polymyositis; ADM, amyopathic dermatomyositis
  2. *Time gap after RS onset referred to the time gap between onset of respiratory symptoms (evident feelings of chest distress and shortness of breath) and PET/CT scan
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us